TILT´s Head of R&D Riikka Havunen successfully defended her PhD thesis “Enhancing adoptive cell therapy of solid tumours with armed oncolytic adenoviruses” on 9th of November 2018. Riikka´s thesis describes the characterization and key preclinical results of TILT-123. Congratulations!
Latest News
Upcoming Events
Please contact our business development team to meet us at the following events:
17-19th September 2024
Nordic Life Science Days (NLSDays)
Malmö, Sweden
27-30th October 2024
16th Annual International Oncolytic Virotherapy Conference
Rotterdam, Netherlands
4-6th November 2024
BIO-Europe
Stockholm, Sweden
20-21st November 2024
SLUSH
Helsinki, Finland
11-13th December 2024
ESMO Immuno-Oncology Congress
Geneva, Switzerland
13-15th January 2025
Biotech Showcase
San Francisco (CA), USA